Profit-taking reverses AEMD's Ebola news surge
Profit-taking reverses AEMD's Ebola news surge, driving 20% drop
- Aethlon Medical's May 21 PR monitoring Bundibugyo Ebola outbreak in Congo/Uganda and reaffirming Hemopurifier preparedness sparked sharp rally
- Stock climbed ~50% from ~$2.05 mid-May lows to $3.07 close on May 27 with 16M volume (vs typical ~200K)
- May 28 closed at $2.94 (-4.23%) on 1.5M volume; selling accelerated May 29 for ~20% loss to near $2.35 area
- No new negative PR, earnings, clinical data, offering, or regulatory update identified on May 28-29
- Micro-cap biotech (market cap ~$4M) with low float exhibits extreme volatility; history of dilutions adds caution
- Retail chatter on X describes move as post-pump shakeout or profit-taking with some buyers adding
- Next potential catalyst is fiscal Q4 2026 earnings expected late June
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.